Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix When Administered in Sri Lankan Infants Aged at Least 6 Weeks at the Time of First Vaccination.

Trial Profile

Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix When Administered in Sri Lankan Infants Aged at Least 6 Weeks at the Time of First Vaccination.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jul 2010

At a glance

  • Drugs RIX 4414 (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Actual patient number (522) added as reported by ClinicalTrials.gov.
    • 10 Jun 2009 Planned end date changed from 1 Jul 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top